Finerenone (CAS 1050477-31-0) is a novel third-generation nonsteroidal mineralocorticoid receptor antagonist (MRA). Unlike traditional steroidal MRAs such as spironolactone, finerenone is structurally distinct and exhibits high selectivity and potency for the mineralocorticoid receptor (MR). It is approved for clinical use under brand names including Kerendia and Firialta.

Finerenone is part of the broader finerenone drug class, which falls under aldosterone antagonists aimed at reducing the harmful effects of aldosterone signaling on the heart and kidneys.

Finerenone functions by selectively blocking the mineralocorticoid receptor (MR), thereby inhibiting the action of aldosterone-a hormone that can promote sodium retention, fibrosis, inflammation, and cardiac and renal damage when overactivated.

It has greater selectivity and potency compared with steroidal MRAs (e.g., spironolactone), meaning it binds more tightly to the MR and has fewer off-target interactions with other hormone receptors (such as androgen or progesterone receptors).

The result is reduced fibrotic and inflammatory signaling in cardiac and renal tissue, contributing to organ protection.

This differentiates finerenone vs spironolactone, with finerenone offering more targeted receptor antagonism and potentially a more favorable safety profile.

Finerenone is indicated for adult patients with chronic kidney disease (CKD) associated with type 2 diabetes mellitus (T2D) to:

• Reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR)
• Lower risk of end-stage renal disease
• Reduce risk of cardiovascular death
• Reduce risk of non-fatal myocardial infarction
• Reduce risk of hospitalization for heart failure

Finerenone is also being investigated in broader cardiovascular populations, including patients with heart failure with preserved or mildly reduced ejection fraction, where it has shown potential benefits in reducing heart failure events and cardiovascular mortality in clinical studies.

Both finerenone and spironolactone belong to mineralocorticoid receptor antagonists, but key differences include:

Finerenone:

Nonsteroidal MRA with high MR selectivity

Lower incidence of hormone-related side effects (e.g., gynecomastia)

Demonstrates cardiorenal protective effects with favorable outcomes in CKD and T2D populations

Spironolactone:

Steroidal MRA with broader receptor activity

Commonly used for heart failure, hypertension, edema, acne, and hirsutism

Higher likelihood of off-target effects due to less selectivity 

Real-world comparative analyses suggest finerenone may have lower risks of major adverse cardiovascular and kidney events and reduced incidence of hyperkalemia compared with spironolactone in CKD and T2D patients. 

Commonly reported effects include:

• Hyperkalemia (elevated potassium)
• Hypotension (low blood pressure)
• Hyponatremia (low sodium)

Serious side effects can include signs of dangerously high potassium or electrolyte imbalance and should prompt immediate medical attention.

Compared with spironolactone, finerenone tends to have a lower incidence of hormone-related adverse effects such as gynecomastia, impotence, or menstrual irregularities due to its high selectivity and nonsteroidal nature.

Finerenone Cost

Retail cost for finerenone (Kerendia) is relatively high compared with generic MRAs. Example pricing for a typical monthly supply runs in the several hundreds of dollars range (approximately $600+ per month in U.S. retail settings, dependent on pharmacy and insurance coverage).

Actual cost may vary based on insurance, coupons, and regional pricing.

Hot Tags:

Finerenone API Supplier, Finerenone Bulk Powder, Finerenone Raw Material, Nonsteroidal MRA API, Mineralocorticoid Receptor Antagonist
Aldosterone Antagonist API, Finerenone Manufacturer, Finerenone Factory Price, Finerenone Pharmaceutical Intermediate,High-Purity Finerenone, GMP Finerenone Supplier, Finerenone API Exporter
 

Message us to get your personalized quotation within 24 hours.

• Whatsapp:+852 6736 4057

• Telegram:@hinovopept

• Email:novopept@gmail.com

Hot Tags: finerenone cas 1050477-31-0, China finerenone cas 1050477-31-0 manufacturers, suppliers, factory